Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance

Multiple myeloma (MM) remains a common hematologic malignancy with a 10-year survival rate below 50%, which is largely due to disease relapse and resistance. The lack of a simple and practical approach to establish myeloma patient-derived xenograft (PDX) hampers translational myeloma research. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Yanhua, Cao, Yang, Mao, Xunyuan, Wang, Fei, Fan, Peng, Qian, Long, Guo, Shuxin, Li, Feng, Guo, Yanting, Chen, Tongbing, Lin, Yan, Dong, Weimin, Liu, Yue, Huang, Yuhui, Gu, Weiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389337/
https://www.ncbi.nlm.nih.gov/pubmed/35992875
http://dx.doi.org/10.3389/fonc.2022.894279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389337/
https://www.ncbi.nlm.nih.gov/pubmed/35992875
http://dx.doi.org/10.3389/fonc.2022.894279

Ejemplares similares